Baker Bros. Advisors LP 13F holdings, Q1 2025
Holdings as of March 31, 2025 · filings on SEC EDGAR · latest filing →
Baker Bros. Advisors LP disclosed 88 US equity positions worth $9.0bn in its Q1 2025 13F filing. The largest position was ONC at 26.5% of the reported book, followed by INCY and ACAD. Against the Q4 2024 filing, it opened 1 new position, added to 8 and reduced 9 among the top 50 holdings.
What did Baker Bros. Advisors LP own in Q1 2025? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2024 |
|---|---|---|---|---|---|---|---|
| 1 | ONC BeiGene, Ltd. | Healthcare | 26.5% | $2.4bn | 8,799,053 | -8% | reduced |
| 2 | INCY Incyte Corporation | Healthcare | 20.6% | $1.9bn | 30,739,953 | 0% | held |
| 3 | ACAD ACADIA Pharmaceuticals Inc. | Healthcare | 7.9% | $712.2m | 42,877,916 | 0% | held |
| 4 | MDGL Madrigal Pharmaceuticals, Inc. | Healthcare | 7.2% | $654.0m | 1,974,590 | 0% | held |
| 5 | SMMT Summit Therapeutics Inc. | Healthcare | 5.2% | $471.2m | 24,424,865 | 0% | held |
| 6 | INSM Insmed Incorporated | Healthcare | 4.5% | $410.5m | 5,380,626 | 7% | added |
| 7 | RYTM Rhythm Pharmaceuticals, Inc. | Healthcare | 3.3% | $296.9m | 5,604,483 | -8% | reduced |
| 8 | RVMD Revolution Medicines, Inc. | Healthcare | 3.1% | $280.7m | 7,936,972 | 0% | held |
| 9 | KYMR Kymera Therapeutics, Inc. | Healthcare | 1.8% | $164.1m | 5,995,929 | 0% | held |
| 10 | ALKS Alkermes plc | Healthcare | 1.6% | $148.0m | 4,483,285 | 7% | added |
| 11 | EWTX Edgewise Therapeutics, Inc. | 1.5% | $135.4m | 6,155,940 | 0% | held | |
| 12 | REPL Replimune Group, Inc. | Healthcare | 1.2% | $107.7m | 11,045,336 | 0% | held |
| 13 | INSM Insmed Incorporated | 1.1% | $101.6m | 42,850,000 | 0% | held | |
| 14 | IMVT Immunovant, Inc. | Healthcare | 1.0% | $93.3m | 5,457,881 | 220% | added |
| 15 | BCYC Bicycle Therapeutics plc | Healthcare | 1.0% | $92.4m | 10,885,357 | 0% | held |
| 16 | IMCR Immunocore Holdings plc | Healthcare | 0.8% | $68.9m | 2,322,656 | 53% | added |
| 17 | Kiniksa Pharmaceuticals International, plc | 0.7% | $62.6m | 2,818,323 | 0% | held | |
| 18 | ABCL AbCellera Biologics Inc. | Healthcare | 0.7% | $61.4m | 27,525,640 | 0% | held |
| 19 | RARE Ultragenyx Pharmaceutical Inc. | Healthcare | 0.6% | $57.1m | 1,576,114 | 0% | held |
| 20 | DNLI Denali Therapeutics Inc. | Healthcare | 0.6% | $50.7m | 3,731,695 | 0% | held |
| 21 | KOD Kodiak Sciences Inc. | Healthcare | 0.5% | $48.6m | 17,310,490 | 0% | held |
| 22 | NRIX Nurix Therapeutics, Inc. | Healthcare | 0.5% | $46.1m | 3,882,125 | 0% | held |
| 23 | ARGX argenx SE | Healthcare | 0.5% | $46.0m | 77,760 | -31% | reduced |
| 24 | TRDA Entrada Therapeutics, Inc. | 0.5% | $44.0m | 4,865,819 | 0% | held | |
| 25 | CELC Celcuity Inc. | Healthcare | 0.5% | $43.0m | 4,257,735 | 59% | added |
| 26 | GRAL GRAIL, Inc. | 0.5% | $41.6m | 1,630,125 | 0% | held | |
| 27 | ROIV Roivant Sciences Ltd. | Healthcare | 0.4% | $38.0m | 3,767,773 | 0% | held |
| 28 | IMTX Immatics N.V. | Healthcare | 0.4% | $32.8m | 7,275,830 | 0% | held |
| 29 | STOK Stoke Therapeutics, Inc. | Healthcare | 0.3% | $30.8m | 4,633,838 | 0% | held |
| 30 | CERS Cerus Corporation | Healthcare | 0.3% | $26.9m | 19,351,087 | -1% | reduced |
| 31 | PCVX Vaxcyte, Inc. | Healthcare | 0.3% | $24.2m | 640,885 | 1211% | added |
| 32 | GLUE Monte Rosa Therapeutics, Inc. | 0.3% | $22.8m | 4,916,095 | 0% | held | |
| 33 | CRSP CRISPR Therapeutics AG | Healthcare | 0.2% | $22.3m | 654,099 | -50% | reduced |
| 34 | Akero Therapeutics, Inc. | 0.2% | $22.2m | 548,713 | -50% | reduced | |
| 35 | SERA Sera Prognostics, Inc. | 0.2% | $20.2m | 5,498,170 | 1% | added | |
| 36 | CNTA Centessa Pharmaceuticals plc | 0.2% | $17.6m | 1,227,178 | 0% | held | |
| 37 | NGNE Neurogene Inc. | 0.2% | $17.4m | 1,486,200 | 120% | added | |
| 38 | IDYA IDEAYA Biosciences, Inc. | Healthcare | 0.2% | $17.4m | 1,062,123 | 0% | held |
| 39 | VRNA Verona Pharma plc | 0.2% | $14.2m | 223,843 | – | new | |
| 40 | CADL Candel Therapeutics, Inc. | 0.2% | $13.8m | 2,437,189 | -18% | reduced | |
| 41 | PRAX Praxis Precision Medicines, Inc. | Healthcare | 0.1% | $12.6m | 331,533 | 0% | held |
| 42 | TSVT* 2seventy bio, Inc. | 0.1% | $12.3m | 2,497,526 | 0% | held | |
| 43 | XENE Xenon Pharmaceuticals Inc. | Healthcare | 0.1% | $11.7m | 347,408 | -65% | reduced |
| 44 | BCAX Bicara Therapeutics Inc. | 0.1% | $10.9m | 833,333 | 0% | held | |
| 45 | IONS Ionis Pharmaceuticals, Inc. | Healthcare | 0.1% | $10.8m | 357,915 | 0% | held |
| 46 | DBVT DBV Technologies S.A. | 0.1% | $10.0m | 1,461,425 | 0% | held | |
| 47 | ALMS Alumis Inc. | 0.1% | $9.6m | 1,562,500 | 0% | held | |
| 48 | Merus N.V. | 0.1% | $9.4m | 223,500 | -50% | reduced | |
| 49 | PRLD Prelude Therapeutics Inc. | 0.1% | $7.8m | 10,123,824 | 0% | held | |
| 50 | Verve Therapeutics, Inc. | 0.1% | $7.7m | 1,691,530 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.